Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review

Frontiers in Immunology

Immunology

Ge Yuan¹  Xiangliang Liu¹  Wei Song¹  Zhongyang Ding¹  Xiao Chen¹  Jin Lu¹  Xinwei Zhang¹ 

[1] Cancer Center of The First Hospital of Jilin University, Changchun, China;

关键词: small cell lung cancer;    immune checkpoint inhibitors;    PD-1;    NLR;    CEA;   

DOI  :  10.3389/fimmu.2023.1267606

 received in 2023-07-26, accepted in 2023-08-29,  发布年份 2023

来源: Frontiers

【 摘 要 】

We report a case of a 59-year-old male diagnosed with extensive-stage small cell lung cancer (SCLC). He received first-line platinum doublet chemotherapy and second-line topotecan-based regimen, but experienced disease progression after each line of therapy. He was then treated with Sintilimab, a PD-1 inhibitor, in combination with nab-paclitaxel in the third-line setting, which resulted in significant tumor shrinkage. Restaging scans showed a partial response per RECIST criteria with 62% reduction in tumor burden. This case highlights the application and efficacy of immune checkpoint inhibitors in extensive-stage SCLC.

【 授权许可】

Unknown   
Copyright © 2023 Yuan, Liu, Zhang, Song, Lu, Ding and Chen

【 图 表 】

fams-09-1177081-i0004.tif

FCHEM_fchem-2023-1253959_wc_tfx2.tif